Study of daunorubicin cardiotoxicity prevention with pyridoxal isonicotinoyl hydrazone in rabbits

Pharmacological Research

Volumn 51, Issue 3, 2005, Pages 223-231

  Simunek T ^a   Klimtova I ^a   Kaplanova J ^b   Sterba M ^c   Mazurova Y ^c   Adamcova M ^c   Hrdina, R ^a   Gersl V ^c   Ponka P ^d  

^a Charles University in Prague Faculty of Pharmacy   (Czech Republic)

^b UNIVERSITY HOSPITAL HRADEC KRALOVE   (Czech Republic)

^c CHARLES UNIVERSITY   (Czech Republic)

^d MCGILL UNIVERSITY   (Canada)

Author keywords

Anthracycline; Cardioprotection; Cardiotoxicity; Daunorubicin; Iron chelator; Pyridoxal isonicotinoyl hydrazone (PIH)

Indexed keywords

DAUNORUBICIN; PYRIDOXAL ISONICOTINOYLHYDRAZONE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARDIOTOXICITY; CONTROLLED STUDY; DRUG EFFECT; HEART EJECTION FRACTION; HEART MUSCLE; HEART PROTECTION; HISTOPATHOLOGY; MALE; NONHUMAN; PRIORITY JOURNAL; SYSTOLIC BLOOD PRESSURE;

ANIMALS; CARDIOTONIC AGENTS; DAUNORUBICIN; HEART VENTRICLES; ISONIAZID; MALE; MYOCARDIUM; PYRIDOXAL; RABBITS;

EID: 12344319022     PISSN: 10436618     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.phrs.2004.08.005     Document Type: Article

References (49)

1. P. Calabresi, and B.A. Chabner Chemotherapy of neoplastic diseases J.G. Hardman LE. Limbird Goodman and Gilman's The pharmacological basis of therapeutics 10th ed 2001 McGraw-Hill New York 1381 1459
2. C. Tan, H. Tasaka, K.P. Yu, M.L. Murphy, and D.A. Karnofsky Daunomycin, an antitumor antibiotic, in the treatment of neoplastic disease. Clinical evaluation with special reference to childhood leukemia Cancer 20 1967 333 353
3. D.D. von Hoff, M. Rozencweig, and M. Piccart The cardiotoxicity of anticancer agents Semin Oncol 9 1982 23 33
4. V.J. Ferrans, J.R. Clark, J. Zhang, Z.X. Yu, and E.H. Herman Pathogenesis and prevention of doxorubicin cardiomyopathy Tsitologiia 39 1997 928 937
5. A. Allen The cardiotoxicity of chemotherapeutic drugs Semin Oncol 19 1992 529 542
6. L.J. Steinherz, P.G. Steinherz, C.T. Tan, G. Heller, and M.L. Murphy Cardiac toxicity 4 to 20 years after completing anthracycline therapy J Am Med Assoc 266 1991 1672 1677
7. P.K. Singal, and N. Iliskovic Doxorubicin-induced cardiomyopathy N Engl J Med 339 1998 900 905
8. S.E. Lipshultz, S.D. Colan, R.D. Gelber, A.R. Perez-Atayde, S.E. Sallan, and S.P. Sanders Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood N Engl J Med 324 1991 808 815
9. L. Gille, and H. Nohl Analyses of the molecular mechanism of adriamycin-induced cardiotoxicity Free Radic Biol Med 23 1997 775 782
10. R.D. Olson, and P.S. Mushlin Doxorubicin cardiotoxicity: analysis of prevailing hypotheses FASEB J 4 1990 3076 3086
11. M.H. Abdel-Wahab, M.A. El-Mahdy, M.F. Abd-Ellah, G.K. Helal, F. Khalifa, and F.M. Hamada Influence of p-coumaric acid on doxorubicin-induced oxidative stress in rat's heart Pharmacol Res 48 2003 461 465
12. G. Link, R. Tirosh, A. Pinson, and C. Hershko Role of iron in the potentiation of anthracycline cardiotoxicity: identification of heart cell mitochondria as a major site of iron-anthracycline interaction J Lab Clin Med 127 1996 272 278
13. J.C. Kwok, and D.R. Richardson Unexpected anthracycline-mediated alterations in iron-regulatory protein-RNA-binding activity: the iron and copper complexes of anthracyclines decrease RNA-binding activity Mol Pharmacol 62 2002 888 900
14. J.C. Kwok, and D.R. Richardson Anthracyclines induce accumulation of iron in ferritin in myocardial and neoplastic cells: inhibition of the ferritin iron mobilization pathway Mol Pharmacol 63 2003 849 861
15. J.C. Kwok, and D.R. Richardson Examination of the mechanism(s) involved in doxorubicin-mediated iron accumulation in ferritin: studies using metabolic inhibitors, protein synthesis inhibitors, and lysosomotropic agents Mol Pharmacol 65 2004 181 195
16. J.L. Buss, and B.B. Hasinoff The one-ring open hydrolysis product intermediates of the cardioprotective agent ICRF-187 (dexrazoxane) displace iron from iron-anthracycline complexes Agents Actions 40 1993 86 95
17. B.B. Hasinoff, K. Hellmann, E.H. Herman, and V.J. Ferrans Chemical, biological and clinical aspects of dexrazoxane and other bisdioxopiperazines Curr Med Chem 5 1998 1 28
18. E.H. Herman, and V.J. Ferrans Preclinical animal models of cardiac protection from anthracycline-induced cardiotoxicity Semin Oncol 25 4 Suppl 10 1998 15 21
19. S.M. Swain, F.S. Whaley, and M.C. Gerber Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer J Clin Oncol 15 1997 1318 1332
20. L.R. Wiseman, C.M. Spencer, and Dexrazoxane A review of its use as a cardioprotective agent in patients receiving anthracycline-based chemotherapy Drugs 56 1998 385 403
21. S.M. Swain, and P. Vici The current and future role of dexrazoxane as a cardioprotectant in anthracycline treatment: expert panel review J Cancer Res Clin Oncol 130 2004 1 7
22. L. Seymour, V. Bramwell, and L.A. Moran Use of dexrazoxane as a cardioprotectant in patients receiving doxorubicin or epirubicin chemotherapy for the treatment of cancer. The Provincial Systemic Treatment Disease Site Group Cancer Prev Control 3 1999 145 159
23. J.L. Buss, M. Hermes-Lima, and P. Poňka Pyridoxal isonicotinoyl hydrazone and its analogues Adv Exp Med Biol 509 2002 205 229
24. M. Adamcova, V. Gersl, R. Hrdina, M. Melka, Y. Mazurova, and J. Vavrova Cardiac troponin T as a marker of myocardial damage caused by antineoplastic drugs in rabbits J Cancer Res Clin Oncol 125 1999 268
25. F.N. Hutchison Proteinuria, hyperlipidemia, and the kidney Miner Electrolyte Metab 19 1993 127 136
26. B.H. Prinsen, M.G. de Sain-van der Velden, E.J. de Koning, H.A. Koomans, R. Berger, and T.J. Rabelink Hypertriglyceridemia in patients with chronic renal failure: possible mechanisms Kidney Int Suppl 84 2003 S121 S124
27. A.V. Hoffbrand Iron chelation therapy Curr Opin Hematol 2 1995 153 158
28. C. Hershko Control of disease by selective iron depletion: a novel therapeutic strategy utilizing iron chelators Baillieres Clin Haematol 7 1994 965 1000
29. C. Hershko, A. Pinson, and G. Link Prevention of anthracycline cardiotoxicity by iron chelation Acta Haematol 95 1996 87 92
30. E.H. Herman, J. Zhang, and V.J. Ferrans Comparison of the protective effects of desferrioxamine and ICRF-187 against doxorubicin-induced toxicity in spontaneously hypertensive rats Cancer Chemother Pharmacol 35 1994 93 100
31. E.E. Voest, S.A. van Acker, W.J. van der Vijgh, B.S. van Asbeck, and A. Bast Comparison of different iron chelators as protective agents against acute doxorubicin-induced cardiotoxicity J Mol Cell Cardiol 26 1994 1179 1185
32. S.Y. Saad, T.A. Najjar, and A.C. Al-Rikabi The preventive role of deferoxamine against acute doxorubicin-induced cardiac, renal and hepatic toxicity in rats Pharmacol Res 43 2001 211 218
33. P. Poňka, J. Borova, J. Neuwirt, O. Fuchs, and E. Necas A study of intracellular iron metabolism using pyridoxal isonicotinoyl hydrazone and other synthetic chelating agents Biochim Biophys Acta 586 1979 278 297
34. D.R. Richardson, M.L. Wis Vitolo, G.T. Hefter, P.M. May, B.W. Clare, and J. Webb Iron chelators of the pyridoxal isonicotinoyl hydrazone class. Part I. Ionisation characterictics of the ligands and their relevance to biological properties Inorg Chim Acta 170 1990 165
35. D.R. Richardson, E.H. Tran, and P. Poňka The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents Blood 86 1995 4295 4306
36. J. Golenser, A. Domb, D. Teomim, A. Tsafack, O. Nisim, and P. Poňka The treatment of animal models of malaria with iron chelators by use of a novel polymeric device for slow drug release J Pharmacol Exp Ther 281 1997 1127 1135
37. N.C. Santos, R.F. Castilho, A.R. Meinicke, and M. Hermes-Lima The iron chelator pyridoxal isonicotinoyl hydrazone inhibits mitochondrial lipid peroxidation induced by Fe(II)-citrate Eur J Pharmacol 428 2001 37 44
38. M. Hermes-Lima, E. Nagy, P. Poňka, and H.M. Schulman The iron chelator pyridoxal isonicotinoyl hydrazone (PIH) protects plasmid pUC-18 DNA against*OH-mediated strand breaks Free Radic Biol Med 25 1998 875 880
39. M. Horackova, P. Poňka, and Z. Byczko The antioxidant effects of a novel iron chelator salicylaldehyde isonicotinoyl hydrazone in the prevention of H(2)O(2) injury in adult cardiomyocytes Cardiovasc Res 47 2000 529 536
40. M. Bhattacharya, P. Poňka, P. Hardy, N. Hanna, D.R. Varma, and P. Lachapelle Prevention of postasphyxia electroretinal dysfunction with a pyridoxal hydrazone Free Radic Biol Med 22 1997 11 16
41. N. Sookvanichsilp, S. Nakornchai, and W. Weerapradist Toxicological study of pyridoxal isonicotinoyl hydrazone: acute and subchronic toxicity Drug Chem Toxicol 14 1991 395 403
42. A. Williams, T. Hoy, A. Pugh, and A. Jacobs Pyridoxal complexes as potential chelating agents for oral therapy in transfusional iron overload J Pharm Pharmacol 34 1982 730 732
43. G.M. Brittenham Pyridoxal isonicotinoyl hydrazone. Effective iron chelation after oral administration Ann NY Acad Sci 612 1990 315 326
44. I. Klimtova, T. Simunek, V. Gersl, R. Hrdina, J. Machackova, and P. Poňka Biochemical and haematological changes following repeated pyridoxal isonicotinoyl hydrazone administration in rabbits Biomarkers Environ 4 Suppl 1 2001 70 75
45. T. Simunek, I. Klimtova, R. Hrdina, V. Gersl, Y. Mazurova, and J. Machackova The effects of repeated administration of pyridoxal isonicotinoyl hydrazone on cardiovascular system in rabbits Biomarkers Environ 4 Suppl 1 2001 93 97
46. M. Adamcova, J. Machackova, V. Gersl, V. Pelouch, T. Simunek, and I. Klimtova Cardiac troponin T following repeated administration of pyridoxal isonicotinoyl hydrazone in rabbits Physiol Res 51 2002 443 448
47. J.F. van Vleet, and V.J. Ferrans Clinical and pathologic features of chronic adriamycin toxicosis in rabbits Am J Vet Res 41 1980 1462 1469
48. D. Deprez-DeCampeneere, R. Jaenke, and A. Trouet Comparative cardiac and renal toxicity of daunorubicin in the rat and rabbit Cancer Treat Rep 66 1982 395 407
49. T. Simunek, I. Klimtova, M. Adamcova, V. Gersl, R. Hrdina, and M. Sterba Cardiac troponin T as an indicator bof reduced left ventricular contractility in experimental anthracycline-induced cardiotoxicity Cancer Chemother Pharmacol 52 2003 431 434